JP2021521171A - 治療用抗体の安定な製剤 - Google Patents

治療用抗体の安定な製剤 Download PDF

Info

Publication number
JP2021521171A
JP2021521171A JP2020555466A JP2020555466A JP2021521171A JP 2021521171 A JP2021521171 A JP 2021521171A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2021521171 A JP2021521171 A JP 2021521171A
Authority
JP
Japan
Prior art keywords
antibody
preparation
sugar
vedolizumab
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521171A5 (enExample
Inventor
ムラリ ジャヤラマン，
ムラリ ジャヤラマン，
アヌジャ チャンドラセカール，
アヌジャ チャンドラセカール，
Original Assignee
ドクター レディズ ラボラトリーズ リミテッド
ドクター レディズ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドクター レディズ ラボラトリーズ リミテッド, ドクター レディズ ラボラトリーズ リミテッド filed Critical ドクター レディズ ラボラトリーズ リミテッド
Publication of JP2021521171A publication Critical patent/JP2021521171A/ja
Publication of JP2021521171A5 publication Critical patent/JP2021521171A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020555466A 2018-04-10 2019-04-10 治療用抗体の安定な製剤 Pending JP2021521171A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841013647 2018-04-10
IN201841013647 2018-04-10
PCT/IN2019/050293 WO2019198101A1 (en) 2018-04-10 2019-04-10 Stable formulations of therapeutic antibody

Publications (2)

Publication Number Publication Date
JP2021521171A true JP2021521171A (ja) 2021-08-26
JP2021521171A5 JP2021521171A5 (enExample) 2022-04-15

Family

ID=68164106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555466A Pending JP2021521171A (ja) 2018-04-10 2019-04-10 治療用抗体の安定な製剤

Country Status (10)

Country Link
US (1) US12433947B2 (enExample)
EP (1) EP3773696A4 (enExample)
JP (1) JP2021521171A (enExample)
CN (1) CN112292146A (enExample)
AU (1) AU2019251453A1 (enExample)
BR (1) BR112020020703A2 (enExample)
CO (1) CO2020013571A2 (enExample)
SG (1) SG11202009876TA (enExample)
WO (1) WO2019198101A1 (enExample)
ZA (1) ZA202006264B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10994011B2 (en) 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2024098180A1 (en) * 2022-11-07 2024-05-16 Wuxi Biologics (Hong Kong) Limited Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
EP4259192A4 (en) * 2020-12-09 2024-11-20 Dr. Reddy's Laboratories Limited STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
US20250092141A1 (en) * 2021-12-27 2025-03-20 Polpharma Biologics S.A. Vedolizumab formulation
EP4615502A1 (en) 2022-11-07 2025-09-17 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530003A (ja) * 2007-06-14 2010-09-02 エラン ファーマシューティカルズ，インコーポレイテッド 凍結乾燥免疫グロブリン製剤および調製方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
CA2690382A1 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
WO2009080541A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US20210322549A1 (en) 2015-07-17 2021-10-21 Coherus Biosciences, Inc. Stable Aqueous Formulations of Natalizumab
CA3143167A1 (en) 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Methods of producing an anti-.alpha.4.beta.7 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530003A (ja) * 2007-06-14 2010-09-02 エラン ファーマシューティカルズ，インコーポレイテッド 凍結乾燥免疫グロブリン製剤および調製方法

Also Published As

Publication number Publication date
AU2019251453A2 (en) 2020-12-03
SG11202009876TA (en) 2020-11-27
EP3773696A4 (en) 2021-12-29
US20210401982A1 (en) 2021-12-30
ZA202006264B (en) 2022-09-28
CO2020013571A2 (es) 2021-01-18
BR112020020703A2 (pt) 2021-01-12
AU2019251453A1 (en) 2020-11-26
US12433947B2 (en) 2025-10-07
CN112292146A (zh) 2021-01-29
EP3773696A1 (en) 2021-02-17
WO2019198101A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7793581B2 (ja) 抗体製剤
US12433947B2 (en) Stable formulations of therapeutic antibody
US11639391B2 (en) Stable liquid pharmaceutical composition
JP2022551622A (ja) インテグリン抗体の安定な製剤
JP2024023468A (ja) 安定な融合タンパク質製剤
EP4243859A1 (en) Stable aqueous high concentration formulation of integrin antibody
EP4259192A1 (en) Stable aqueous buffer free formulation of an integrin antibody
US12024561B2 (en) Stable antibody formulation
WO2023031970A1 (en) A pharmaceutical formulation of immune check point inhibitors
EP4398932A1 (en) Formulations of immune check point inhibitors or like
WO2025037335A1 (en) Formulations of anti-cd20 antibody
EP4398931A1 (en) Formulations of immune check point inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230814